News

Enzon has initiated the phase-II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers in US to patients diagnosed with metastatic

Neovacs plans to initiate a phase-II study of its TNF Kinoid, subject to regulatory consent, in rheumatoid arthritis patients who have failed treatment with at least one TNF

Perceptive, a subsidiary of PAREXEL International, has launched the next level of technology integration in eClinical Suite, which provides flawless integration and access to data across multiple technologies

Sparta Systems has launched TrackWise Clinical Quality Management Solution. It is meant to provide an end-to-end system that streamlines the oversight of business-critical clinical trial processes, and help

BioLineRx has reported new results confirming its GABA enhanced BL-1020 drug’ MOA. BL-1020 is an orally available antipsychotic for the treatment of schizophrenia. BL-1020 has recently completed a

Cannabis Science (Cannabis) is all set to file patent for two of its key innovations, processing systems and drug delivery systems. Cannabis’ management has authorized expenditures for patents, the innovations will be

Hospira has announced that the US District Court for New Jersey, has granted summary judgment of non-infringement in Hospira’ favour, with regard to Sanofi Aventis’ chemotherapy medication, Eloxatin. The

GTC Biotherapeutics (GTC) has signed agreements with LFB (a wholly-owned subsidiary of LFB S.A) to provide a total of $12.3 million of cash proceeds to GTC, with an option

The Medicines Company has received FDA’ pediatric exclusivity for Angiomax (bivalirudin), based on studies submitted in response to a written request by FDA, for pediatric patients aged under 16.